StageSeed VC | Alive
Last Raised$2.02M | 2 yrs ago
Glyconics develops a non-invasive handheld diabetes screening device. The device exploits the use of miniaturized infra-red (IR) spectrometry for the early diagnosis of diabetes by detecting biomarker changes in a patient’s fingernail.
Missing: Glyconics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Glyconics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Glyconics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Glyconics in 2 CB Insights research briefs, most recently on Oct 28, 2022.
Expert Collections containing Glyconics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Glyconics is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest Glyconics News
Feb 20, 2023
New research reveals that advisers prefer EIS to VCT written by LLB Reporter 20th Feb 23 9:55 am A new adviser survey by tax efficient investment manager, Deepbridge Capital, suggests that financial advisers utilise Enterprise Investment Scheme (“EIS”) investment opportunities more than Venture Capital Trusts (“VCTs”) . When asked whether they tend to use EIS funds or VCTs more often, one in ten (11%) suggested they only use EIS. This is compared to just 2% of respondents who use VCTs exclusively. Nearly a third (31%) use both EIS and VCT equally, with a further 26% stating that they use EIS ‘predominantly,’ but do also utilise VCTs when appropriate. 82% of advisers also state that speed of deployment is a ‘very important’ factor when selecting an EIS manager, with the other 18% suggesting that this be a ‘fairly important’ criterion. The EIS is a Government scheme that provides a range of tax reliefs for investors who subscribe for qualifying shares in qualifying companies, including income tax relief, capital gains tax deferral, CGT-free growth, inheritance tax mitigation and share loss relief. VCTs are similar to investment trusts and are managed by fund managers, with investors subscribing for shares in a VCT, which then onward invests in qualifying trading companies, with tax reliefs including income tax relief, CGT-free growth and tax free dividends. Andrew Aldridge, Partner at Deepbridge Capital and Board Member of The Enterprise Investment Scheme Association (EISA), commented: “Given last year’s record fundraising by VCTs, you would be forgiven for thinking that they are the primary tax efficient investment planning tool used by financial advisers, but this survey suggests otherwise. “It is reassuring to know that the Enterprise Investment Scheme continues to be a key tool for advisers when tax planning and seeking long-term growth opportunities. Given the current macroeconomic climate, EIS has never been more important for investors, advisers and, critically, the growth-focused early-stage companies for whom EIS funding is invaluable.” Kam Pooni, CEO at Glyconics, which has received EIS funding added; “The Enterprise Investment Scheme is globally envied, and provides UK based innovators with vital funding that can be transformational. This has been the case for us at Glyconics as we seek to revolutionise the medical diagnostics and biomarker analysis industries, by taking our impressive R&D results into the commercial arena.” Michael White, Managing Director at Capital Wealth Partners, concluded; “Both EIS and VCTs provide financial advisers with fantastic tax planning tools, whilst also encouraging investors to back early-stage unlisted stocks, which could provide significant long-term growth. Within a diversified and balanced portfolio, all financial advisers should be considering EIS investments for appropriate clients.” Leave a Comment
Glyconics Frequently Asked Questions (FAQ)
When was Glyconics founded?
Glyconics was founded in 2013.
Where is Glyconics's headquarters?
Glyconics's headquarters is located at Trafalgar House, Meridian Business Park, Norwich.
What is Glyconics's latest funding round?
Glyconics's latest funding round is Seed VC.
How much did Glyconics raise?
Glyconics raised a total of $2.02M.
Who are the investors of Glyconics?
Investors of Glyconics include Boundary Capital, Deepbridge Capital and Wealth Club.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.